论文部分内容阅读
目的:探讨糖尿病合并冠心病采用曲美他嗪治疗的临床效果。方法:选择我院2011年6月至2012年6月收治的糖尿病合并冠心病患者100例,随机分为观察组和对照组各50例,对照组采用基础药物治疗,观察组在对照组的基础上加用曲美他嗪治疗,回顾对比分析两组资料。结果:观察组50例总有效率为94%,对照组50例总有效率为68%,差异有统计学意义(P<0.05)。观察组心绞痛发作频率、持续时间、硝酸甘油使用量明显少于对照组,血糖、血脂水平明显低于对照组,差异有统计学意义(P<0.05)。结论:糖尿病合并冠心病采用曲美他嗪治疗,可显著提高临床效果,降低血脂及血糖水平,减少心绞痛发作时间和频率,加快疾病康复进程。
Objective: To investigate the clinical effect of trimetazidine on diabetic patients with coronary heart disease. Methods: One hundred patients with diabetes mellitus complicated with coronary heart disease admitted in our hospital from June 2011 to June 2012 were randomly divided into observation group and control group, 50 cases in each group. The control group was treated with basic drugs and the observation group was basal in the control group Trimetazidine plus treatment, review the comparative analysis of two sets of data. Results: The total effective rate was 94% in observation group and 50% in control group, the total effective rate was 68%. The difference was statistically significant (P <0.05). The frequency and duration of angina pectoris in observation group were significantly less than those in control group, and the levels of blood glucose and blood lipid were significantly lower than those in control group. The difference was statistically significant (P <0.05). Conclusion: Trimetazidine treatment of diabetic patients with coronary heart disease can significantly improve the clinical efficacy, lower blood lipids and blood glucose levels, reduce angina pectoris onset time and frequency, and speed up the process of disease rehabilitation.